SCHEDULE: Paradigm BioCapital Discloses 5.1% Stake in EyePoint

Paradigm BioCapital Advisors LP and related entities have disclosed a 5.1% beneficial ownership stake in EyePoint, Inc. common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. collectively reported beneficial ownership of 4,192,261 shares of EyePoint, Inc. common stock.
• This aggregate ownership represents 5.1% of EyePoint, Inc.'s outstanding common stock.
• Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 3,694,542 shares, representing 4.5% of the class.
• The percentages are based on 82,787,220 shares of Common Stock outstanding as of October 30, 2025, as reported by EyePoint, Inc. in its Form 10-Q.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of EyePoint, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a specialized institutional investor has disclosed a significant, passive stake in EyePoint, Inc., indicating potential confidence in the company's long-term prospects without seeking control.

Positives

• A significant institutional investor, Paradigm BioCapital, has taken a notable stake in EyePoint, Inc., potentially signaling confidence in the company's future.
• The filing indicates a passive investment intent, as the securities were not acquired for the purpose of changing or influencing control.

Negatives

• No specific negative information is contained within this beneficial ownership disclosure.

Risks

• No specific risks related to EyePoint, Inc.'s operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding EyePoint, Inc.'s future performance or strategic direction.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by a specialized biopharmaceutical investor like Paradigm BioCapital could be interpreted as a positive signal within the competitive biotechnology and pharmaceutical industry, where investor confidence is crucial for growth and development.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may instill confidence and potentially attract further institutional interest, which could positively impact share price stability and liquidity.
• Management: Management may view this as a vote of confidence in their strategy, given the passive nature of the investment.

Key Dates

Recommendation

The filing indicates a significant institutional investor has taken a passive stake in EyePoint, Inc., which is generally a positive signal of confidence. However, without additional financial or operational updates, a 'hold' recommendation is appropriate, suggesting investors monitor future developments and the company's performance.

Keywords

EyePoint Inc, EYPT, Paradigm BioCapital, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals